The Medical Research Commercialisation Fund has supplied series A capital to Okogen as the company partners University of Sydney to develop a treatment for viral conjunctivitis.
Okogen, a US-based developer of treatments for eye diseases, raised A$13m ($10m) in a series A round today from Medical Research Commercialisation Fund (MRCF), managed by Brandon Capital.
Founded in 2016, Okogen is working on treatments for ocular infections. The company’s lead candidate, OKG-0301, functions within cells to prevent viruses from replicating.
The treatment is initially being targeted at adenoviral conjunctivitis, a leading cause for eye infections that does not currently have an approved therapy.
The series A funding will…
